Three-dimensional triangular DNA nanoarriers for folate receptor-targeted therapy of takayasu arteritis

A three-dimensional triangular DNA origami nanostructure targets M1 macrophages in Takayasu arteritis, promoting their polarization to the M2 phenotype and delivering therapeutic agents, effectively reducing inflammation and reversing fibrosis with minimal side effects.

WO2026233525A1PCT designated stage Publication Date: 2026-11-12YOUSRY MOHAMED NOURHAN +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EG2025/050016
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current treatments for Takayasu arteritis, including glucocorticoids and biologic drugs, are inadequate in preventing cardiac tissue fibrosis and reversing arterial wall damage, with high relapse rates and significant adverse effects, while existing biologics fail to effectively target the pro-inflammatory M1 macrophages driving the disease.

Method used

A three-dimensional triangular DNA origami nanostructure functionalized with folic acid to target folate receptors on M1 macrophages, promoting their polarization to the anti-inflammatory M2 phenotype, and encapsulating therapeutic agents for targeted immunomodulation and tissue regeneration.

Benefits of technology

The nanostructure selectively targets M1 macrophages, reducing inflammation, reversing fibrosis, and promoting vascular healing, offering a broader, sustained immunomodulatory effect with reduced systemic toxicity and reliance on glucocorticoids.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000001_0001
    Figure IMGF000001_0001
  • Figure IMGF000002_0001
    Figure IMGF000002_0001
  • Figure IMGF000002_0002
    Figure IMGF000002_0002
Patent Text Reader

Abstract

In a representative embodiment, described herein is a targeting therapeutic approach comprising a three-dimensional triangular DNA-based nanocarrier designed to reach on macrophages involved in driving inflammation in autoimmune vascular disorders, particularly Takayasu arteritis, enabling the precise delivery of anti-inflammatory therapies at the disease site. The nanostructure is constructed through DNA origami techniques, wherein a longsingle-stranded scaffold nucleic acid derived from M13mp18, and a plurality of shorter staple strands configured to fold a three-dimensional scaffold into a triangular prism-shaped conformation. The nanostructure is engineered to carry one or more therapeutic agents, including but not limited to anti-inflammatory compounds, immunomodulatory nucleic acids, or biologically active peptides. Agents may be encapsulated within or conjugated to the surfaces of the DNA-origami nanostructure. The configuration enables stability in circulation, protection of the payload, and controlled release upon cellular uptake. In specific embodiments, the outer surface of the nanostructure is functionalized or conjugtaed with folic acid that bind with high specificity and affinity to folate receptors expressed on pro-inflammatory M1 macrophages. This enables selective targeting and uptake into the pathological macrophage population present at the inflamed regions of the aorta in Takayasu arteritis. In a representative therapeutic application, the clinically effective dose of the therapeutic approach of the DNA-origami nanostructre encapsulated therapeutic compound delivery is via intravenous administration. Upon cellular uptake the nanostructure facilitates the phentypic reprogramming of M1 macrophages into the anti-inflammatory M2 phenotype, thereby contributing to mitigatation and suppression of vascular inflammation. The described nanoplatform is biocompatible, programmable, and highly specific disease-targeted nanoplatform fortreatingTakayasu arteritis, enabelingfocused therapy that reduces or even eliminates side effects, while maximizing the effect at the affected site.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Title of the Invention: Three-Dimensional Triangular DNA Nanoarriers for Folate Receptor-Targeted Therapy of Takayasu Arteritis

[0002] Technical Field

[0003] The present invention relates to the field of biomedical nanotechnology and nanomedicine. More particularly, it pertains to targeted drug delivery systems utilizing DNA origami nanostructures for immunomodulation and therapeutic intervention in autoimmune and inflammatory vascular diseases. Specifically, the invention provides a folate-functionalized, three-dimensional DNA origami nanocarrier for the selective delivery of anti-inflammatory and tissue-regenerative agents to pro-inflammatory M1 macrophages, with application in the treatment of Takayasu arteritis.

[0004] Sources:

[0005] Bhandari, S., Butt, S. R. R., Ishfaq, A., Attaallah, M. H., Ekhator, C., Halappa Nagaraj, R., Mulmi, A., Kamran, M., Karski, A., Vargas, K. I., Lazarevic, S., Zaman, M. U., Lakshmipriya Vetrivendan, G., Shahzed, S. M. I., Das, A., Yadav, V., Bellegarde, S. B., & Ullah, A. (2023). Pathophysiology, Diagnosis, and Management of Takayasu Arteritis: A Review of Current Advances. Cureus, 15(7), e42667.

[0006]

[0007] Campochiaro, C., Tomelleri, A., Sartorelli, S., Cavalli, G., De Luca, G., Baldissera, E., & Dagna, L. (2020). Drug retention and discontinuation reasons between seven biologies in patients with Takayasu arteritis. In Seminars in Arthritis and Rheumatism (Vol. 50, No.

[0008] 3, pp. 509-514). WB Saunders.

[0009] Di Benedetto, P., Ruscitti, P., Vadasz, Z., Toubi, E., & Giacomelli, R. (2019). Macrophages with regulatory functions, a possible new therapeutic perspective in autoimmune diseases. Autoimmunity reviews, 18(10), 102369.

[0010] Fan, Y, Wang, C„ Dai, W„ Zhou, Y, Lu, G„ Li, W„... & Lin, T. (2024). DNA Origami Enhanced Cytokine Immunotherapy for Alleviating Renal Ischemia-Reperfusion Injury. ACS Applied Materials & Interfaces, 16(30), 38979-38988.

[0011] Guan, C., Zhu, X., & Feng, C. (2021). DNA nanodevice-based drug delivery systems. Biomolecules, 11(12), 1855.

[0012] He, Z., Xiang, W., Fan, Q., Wang, L., & Chao, J. (2023). A DNA Origami Nanostructure Embedded with NQO1 -Activated Prodrugs for Precision Drug Delivery. Chemical Communications, 59(7), 912-915.

[0013] Hellmich, B., Agueda, A., Monti, S., Buttgereit, F., de Boysson, H., Brouwer, E., Cassie, R., Cid, M. C., Dasgupta, B., Dejaco, C., Hatemi, G., Hollinger, N., Mahr, A., Mollan, S. P.,Mukhtyar, C., Ponte, C., Salvarani, C., Sivakumar, R., Tian, X., Tomasson, G.,... Luqmani, R. A. (2020). 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Annals of the rheumatic diseases, 79(1), 19-30.

[0014]

[0015] Hu, Q., Li, H., Wang, L., Gu, H., & Fan, C. (2019). DNA Nanotechnology-Enabled Drug Delivery Systems. Chemical reviews, 119(10), 6459-6506.

[0016] Ijas, H., Hakaste, I., Shen, B., Kostiainen, M. A., & Linko, V. (2019). Reconfigurable DNA Origami Nanocapsule for pH-Controlled Encapsulation and Display of Cargo. ACS Nano, 13(5), 5959-5967.

[0017] Jiang, D., Ge, Z., Im, H. J., England, C. G., Ni, D., Hou, J., Zhang, L, Kutyreff, C. J., Yan, Y„ Liu, Y., Cho, S. Y., Engle, J. W., Shi, J., Huang, P., Fan, C., Yan, H., & Cai, W. (2018). DNA origami nanostructures can exhibit preferential renal uptake and alleviate acute kidney injury. Nature biomedical engineering, 2(11), 865-877.

[0018] Kang, E. J., Kim, S. M„ Choe, Y. H„ Lee, G. Y, Lee, K. N„ & Kim, D. K. (2014). Takayasu arteritis: assessment of coronary arterial abnormalities with 128-section dual-source CT angiography of the coronary arteries and aorta. Radiology, 270(1 ), 74-81.

[0019]

[0020] Kong, X., Xu, M„ Cui, X., Ma, L„ Cheng, H„ Hou, J., Sun, X., Ma, L„ & Jiang, L. (2021 ). Potential Role of Macrophage Phenotypes and CCL2 in the Pathogenesis of Takayasu Arteritis. Frontiers in immunology, 12, 646516.

[0021]

[0022] Li, R„ Li, W„ Zhou, Y, Liao, G„ Peng, G„ Zhou, Y, Gou, L„ Zhu, X., Hu, L„ Zheng, X., Wang, C., & Tong, N. (2024). A DNA-based and bifunctional nanomedicine for alleviating multi-organ injury in sepsis under diabetic conditions. Acta biomaterialia, 177, 377- 387. https: / / doi. Org / 10.1016 / j.actbio.2024.01.036

[0023] Lucas, C. R., Halley, P. D., Chowdury, A. A., Harrington, B. K., Beaver, L., Lapalombella, R., Johnson, A. J., Hertlein, E. K., Phelps, M. A., Byrd, J. C., & Castro, C. E. (2022). DNA Origami Nanostructures Elicit Dose-Dependent Immunogenicity and Are Nontoxic up to High Doses In Vivo. Small (Weinheim an der Bergstrasse, Germany), 78(26), e2108063. Lucas, C. R., Halley, P. D., Chowdury, A. A., Harrington, B. K., Beaver, L., Lapalombella, R„ Johnson, A. J., Hertlein, E. K„ Phelps, M. A., Byrd, J. C„ & Castro, C. E. (2022). DNA Origami Nanostructures Elicit Dose-Dependent Immunogenicity and Are Nontoxic up to High Doses In Vivo. Small (Weinheim an der Bergstrasse, Germany), 18(26), e2108063.

[0024]

[0025] Ma, Y., Lu, Z., Jia, B., Shi, Y, Dong, J., Jiang, S., & Li, Z. (2022). DNA Origami as a Nanomedicine for Targeted Rheumatoid Arthritis Therapy through Reactive Oxygen Species and Nitric Oxide Scavenging. ACS nano, 16(8), 12520-12531.Maezawa, T., Ohtsuki, S., Hidaka, K., Sugiyama, H., Endo, M., Takahashi, Y, Takakura, Y., & Nishikawa, M. (2020). DNA density-dependent uptake of DNA origami-based two-or three-dimensional nanostructures by immune cells. Nanoscale, 12(27), 14818-14824. Martin-Sabroso, C., Torres-Suarez, A. I., Alonso-Gonzalez, M., Fernandez-Carballido, A., & Fraguas-Sanchez, A. I. (2022). Active Targeted Nanoformulations via Folate Receptors: State of the Art and Future Perspectives. Pharmaceutics, 14(1), 14.

[0026] Misra, D. P., Wakhlu, A., Agarwal, V., & Danda, D. (2019). Recent advances in the management of Takayasu arteritis. International journal of rheumatic diseases, 22, 60-68.

[0027] Nasiri, M., Bahadorani, M., Dellinger, K., Aravamudhan, S., Vivero-Escoto, J. L., & Zadegan, R. (2024). Improving DNA Nanostructure Stability: A Review of the Biomedical Applications and Approaches. International Journal of Biological Macromolecules, 260(Pt 1), 129495.

[0028] Pal, S., & Rakshit, T. (2021). Folate-Functionalized DNA Origami for Targeted Delivery of Doxorubicin to Triple-Negative Breast Cancer. Frontiers in Chemistry, 9, 721105.

[0029] Regola, F., Uzzo, M., Toniati, P., Trezzi, B., Sinico, R. A., & Franceschini, F. (2022). Novel therapies in Takayasu arteritis. Frontiers in Medicine, 8, 814075.

[0030] Sanada, F., Fujikawa, T., Shibata, K., Taniyama, Y, Rakugi, H., & Morishita, R. (2020). Therapeutic Angiogenesis Using HGF Plasmid. Annals of vascular diseases, 13(2), 109- 15.

[0031] Sanchez-Alvarez, C., Crowson, C. S., Koster, M. J., & Warrington, K. J. (2021). Prevalence of Takayasu arteritis: a population-based study. The Journal of rheumatology, 48(6), 952-952.

[0032] Schmidt, K. T., Huitema, A. D. R., Dorio, T. P. C., et al. (2020). Population Pharmacokinetic Analysis of Nanoparticle-Bound and Free Camptothecin after Administration of NLG207 in Adults with Advanced Solid Tumors. Cancer Chemotherapy and Pharmacology, 86(4), 475-486.

[0033] Sellner, S., Kocabey, S., Zhang, T., Nekolla, K., Hutten, S., Krombach, F., Liedl, T., & Rehberg, M. (2017). Dexamethasone-conjugated DNA nanotubes as anti-inflammatory agents in vivo. Biomaterials, 134, 78-90.

[0034] Song, T., Wang, X., Li, X., & Zheng, P. (2017). A programming triangular DNA origami for doxorubicin loading and delivering to target ovarian cancer cells. Oncotarget, 5.

[0035] Thomas, T. P., Goonewardena, S. N., Majoros, I. J., Kotlyar, A., Cao, Z., Leroueil, P. R., et al. (2011). Folate-Targeted Nanoparticles Show Efficacy in the Treatment of Inflammatory Arthritis. Arthritis & Rheumatism, 63(3), 2671-2680.Wang, H., Jiao, Y, Ma, S., Li, Z., Gong, J., Jiang, Q., Shang, Y., Li, H., Li, J., Li, N., Zhao, R. C., & Ding, B. (2024). Nebulized Inhalation of Peptide-Modified DNA Origami To Alleviate Acute Lung Injury. Nano letters, 24(20), 6102-6111.

[0036] Wang, H., Liu, Z., Shen, Z., Fang, L., & Zhang, S. (2020). Impact of coronary involvement on long-term outcomes in patients with Takayasu's arteritis. Clinical and experimental rheumatology, 38(6), 1118-1126.

[0037] Ye, W., Chen, X., Li, X., Liu, Y., Jia, F., Jin, Q., & Ji, J. (2020). Structure-Switchable DNA Programmed Disassembly of Nanoparticles for Smart Size Tunability and Cancer- Specific Drug Release. ACS appf / edmater / ate<& / nterfeces, 72(20), 22560-22571.

[0038] Zhang, Y., Tian, X., Wang, Z., Wang, H., Liu, F., Long, Q., & Jiang, S. (2023). Advanced applications of DNA nanostructures dominated by DNA origami in antitumor drug delivery. Frontiers in molecular biosciences, 10, 1239952.

[0039] Zhu, Y., Shi, R., Lu, W., Shi, S., & Chen, Y. (2024). Framework nucleic acids as promising reactive oxygen species scavengers for anti-inflammatory therapy. Nanoscale, 16(15), 7363-7377.

[0040] Background Art:

[0041] Takayasu arteritis (TAK) is a rare autoimmune disease and a type of large vessel vasculitis that causes chronic inflammation in large arteries, particularly the aorta and its major branches, and is associated with life-threatening events. Chronic inflammation and arterial wall damage caused by the disease can result in a variety of consequences, including stenosis, aneurysm formation, and arterial occlusion. These issues can cause organ ischemia, hypertension, and potentially life-threatening events like a stroke or myocardial infarction (Bhandar et al., 2023). The chronic inflammation in TAK may affect the entire aorta, including all aortic branches. Although the most often impacted vessels are the thoracic and abdominal aorta, up to one-third of TAK patients have been shown to have heart involvement. Heart symptoms can include myocardial, valvular, and coronary involvement; in addition, coronary computed tomography angiography (CTA) revealed coronary lesions in up to 53% of TAK patients (Kang et al., 2014; Wang et al., 2020).

[0042] The incidence rate means how many new cases of TAK appear each year, ranging from 0.3 to 3.3 per million per year, whereas the prevalence rate shows how many people in total are living with the disease, which ranges from 4.7 to 360 cases per million and it is more prevalent in women than in men (Sanchez-Alvarez et al., 2021).

[0043] The pathogenesis of TAK begins when immune tolerance is disrupted, when abnormal vascular dendritic cells become activated by unknown triggers and secrete pro-inflammatory cytokines, attracting vasculitogenic T cells into the arterial wall. These Tcells, along with cytotoxic CD8+ T cells and pro-inflammatory M1 macrophages, drive acute inflammation through the release of cytokines, perforin, granzymes, and matrix metalloproteinases. In addition, pro-inflammatory M1 macrophages contribute to the development of vascular lesions and acute vascular inflammation by secreting inflammatory cytokines, including IL-1 p, IL-6, and tumor necrosis factor-a (TNF-a), as well as inflammatory chemokines, including CCL5, CCL8, CXCL12, and CXCL4. In addition, M1 macrophages also produce reactive oxygen species, nitric oxide (NO), and matrix metalloproteinases that weaken and degrade the tunica media, which is the middle layer in the blood vessel wall. While M2 macrophages secrete anti-inflammatory cytokines that present and contribute to the dormant phase in TAK by promoting tissue repair and modulating the inflammatory response (Di Benedetto et al., 2019; Kong et al., 2021; Regola et al., 2022)

[0044] Systemic glucocorticoids (GC) are the mainstay medication used to induce remission in TAK. Most patients initially achieve illness remission; however, relapses or disease progression are found in more than 50% of patients during GC tapering. Moreover, GC therapy has adverse side effects, including hypertension, early cardiovascular disease, infections, osteoporosis, and growth restriction in children (Regola et al., 2022). Also, cardiovascular risk factors are made worse with GC treatment as GC treatment raises blood pressure in a dose-dependent manner, mediated by increased peripheral vascular resistance and a direct impact on the mineralocorticoid receptor. GC therapy also raises the risk of dyslipidaemia, glucose intolerance, diabetes, and central obesity (Hellmich et al., 2020).

[0045] Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) are also added to GC to induce remission in TAK, as the monotherapy of GC has failed in 70% of TAK patients. These csDMARDs comprise methotrexate, mycophenolate mofetil, leflunomide, azathioprine, and cyclophosphamide. The usage of csDMARDs is associated with inducing remission, as methotrexate demonstrated effectiveness in controlling the disease, but the effect of csDMARDs on blood vessel damage is not obvious, and the relapse rate of TAK patients treated with csDMARDs is High, also a lot of patients have contraindications to csDMARDs. In addition, it was demonstrated that cyclophosphamide has an increased risk of long-term adverse effects and infertility (Misra et al., 2019; Regola et al., 2022).

[0046] The prior art also included the usage of biological disease-modifying anti-rheumatic drugs (bDMARDs) that include TNF-a Inhibitors, anti-IL-6 receptor agents, and anti-CD20 monoclonal antibodies.

[0047] The usage of anti-CD20 therapy has been ineffective in controlling vascular inflammation. Also, anti-IL-6 receptor agents show less efficiency in controlling the inflammation than TNF-a Inhibitors, and the efficacy of anti-IL-6 receptor drugs appears to fade if subsequent infusions are not delivered; thus, their purpose is likely to be a stop-gap therapy. Although TNF-a Inhibitors show high efficacy in controlling the disease, it is frequently required to be given to the patient in high doses and always need dose escalation, which may cause safety concerns, and not all patients respond; some become refractory to the therapy (Campochiaro et al., 2020; Misra et al., 2019; Regola et al., 2022

[0048] Detailed Description:

[0049] In one embodiment, the geometry of the DNA-Origami is critically affects circulation and biodistribution. The DNA origami nanostructure is chosen to support favorable pharmacokinetics and vascular targeting performance. In the context of large vessel inflammation, such as that seen in Takayasu arteritis affectingthe aorta, the ability of the nanostructure to circulate for extended periods and engage with the vessel wall is essential. While rod-like DNA origami have demonstrated benefits in aligning with blood flow and avoiding rapid hepatic filtration, the present invention utilizes a three-dimensional triangular configuration designed to retain those advantages while also providing structural compactness and enhanced surface area for ligand presentation (Lucas et al., 2022). Compact 3D designs (e.g. a triangular prism) have more DNA per volume and are taken up by immune cells more readily than flat tiles (Maezawa et al., 2020). The triangular prism design disclosed herein is similarly expected to confer geometric stability and flow-compatible orientation under arterial shear conditions. The triangular structure further offers defined planar surfaces suitable for targeted ligand presentation and facilitates contact with the vascular endothelium at sites of inflammation (Lucas et al., 2022). In certain embodiment, the nanostructure is assembled by folding a long single-stranded DNA scaffold, preferably a modified form of the M13mp18 bacteriophage genome (approximately 7,249 nucleotides in length), using a defined set of complementary short staple strands. These staple strands are designed to bind at specific intervals along the scaffold, inducing the folding of the scaffold into a rigid triangular prism configuration. This approach is consistent with established DNA origami techniques utilizing the M13mp18 scaffold (Song et al., 2017). The design and routing of the scaffold and staples are achieved using standard DNA nanostructure design software such as caDNAno, and the triangular shape is maintained through well-defined crossover junctions between adjacent helices. In the design relevant to this invention, the DNA origami is configured to form a triangular nanostructure with each edge measuring approximately 90 nanometers, as reported in prior work by Ma et al. (2022). In a preferred, though non-limiting, embodiment, the DNA origami nanostructure is configured as a three-sided polygonal geometry, more specifically a triangular framework, exhibiting lateral edge lengths on the order of approximately 90 nanometers. This size range is illustrative and may be varied as necessary to accommodate different therapeutic or pharmacokinetic objectives. The nanostructure is designed to exhibit lateral dimensions between approximately 50 nm and 100 nm along its triangular edges, with a thickness ranging from approximately 2 nm to 10 nm, depending on the layeringscheme employed. In certain embodiments, a multi-layered design is utilized, wherein multiple DNA helices are arranged in parallel to form a structurally reinforced core. Such multilayer architectures have been reported to posses increased resistance to enzymatic degradation and mechanical stress, thereby enhancing the nanostructure’s in vivo persistence. The surface topology may be adapted to support the site-specific attachment of biological ligands, targeting molecules, or therapeutic payloads. In one preferred embodiment, The conjugation of folate to the staple strands is accomplished through covalent linkage, employing chemistries such as click reactions or amide bond formation, ensuring stable attachment and preserving the binding affinity of the folate ligands. The density and distribution of the folate moieties are optimized to maximize receptor-mediated endocytosis while minimizing off-target interactions. In preferred embodiments, the exterior-facing staple strands of the origami nanostructure are functionalized with folic acid (FA) or folate-conjugated aptamers to enable selective targeting of folate receptor beta (FR ), which is overexpressed on pro-inflammatory M1 macrophages commonly found in Takayasu arteritis lesions. Conjugation of folic acid to DNA origami is performed through covalent attachment at amine-modified or thiol-modified staple termini, using crosslinking chemical compounds including but not limited to EDC / NHS coupling, maleimide-thiol reaction, orstrain-promoted azide-alkyne cycloaddition (SPAAC), depending on the functional groups present on the folic acid derivative. In some embodiments, folic acid ligands were conjugated to amine-modified oligonucleotides (FA-oligo) via N-hydroxysuccinimide (NHS) chemistry and subsequently anchored to staple strand overhangs, facilitating surface localization of targeting moieties in a spatially controlled manner. While the specific sequence design and crossover architecture are not fixed in the present disclosure (Hu et al., 2019; Jiang et al., 2018). The interior cavity of the triangular prism nanostructure serves as a reservoir for the encapsulation of therapeutic agents aimed at modulating macrophage polarization (Guan et al., 2021; Fan et al., 2024; Wang et al., 2024). In some embodiments, the DNA-origami may includes but not limited to anti-inflammatory compounds, immunomodulatory nucleic acids, or biologically active peptides (Sellner et al., 2017; Fan et al., 2024; Wang et al., 2024). Furthermore, it may includes tissuerepairing and pro-regenerative compounds agents comprising but not limited to Hepatocyte Growth Factor (HGF), which is anti-fibrotic and pro-regenerative in vascular tissue. Wherein said Hepatocyte Growth Factor (HGF) is configured to stimulates endothelial regeneration without promoting fibrosis (Sanada et al., 2020). may be encapsulated within or conjugated to the surfaces of the DNA-origami nanostructure via cleavable linkers that respond to intracellular stimuli, such as acidic pH or specific enzymatic activity (Ye et al., 2020). The configuration enables stability in circulation, protection of the payload, and controlled release upon cellular uptake (Zhang et al., 2023; Ye et al., 2020). In certain embodiments, the DNA-origami nanostructures conjugated with folic acid as described herein may be administered via parenteral routes, including but not limited to intravenous (IV), intramuscular (IM), and subcutaneous (SC)injections (Lucas et al., 2022). The selection of the administration route is influenced by various factors, including the physicochemical properties of the nanostructure formulation, desired pharmacokinetic profiles, and therapeutic objectives (Schmidt et al., 2020; Nasiri et al., 2024). Wherein, Intravenous administration employed, it depends on the immediate systemic availability is required. Also, formulations suitable for this route typically exhibit complete solubility, isotonicity, and stability in physiological conditions, facilitating rapid systemic distribution (Nasiri et al., 2024). Wherein, intramuscular administration utilized a controlled or sustained release is advantageous. In such embodiments, the formulation may be prepared to allow gradual absorption from the injection site, thereby extending the duration of therapeutic effect (Schmidt et al., 2020). Subcutaneous administration may be appropriate for formulations that require slower systemic absorption, and may be preferable in scenarios demanding lower volumes and minimal patient discomfort (Schmidt et al., 2020). The choice amongthese administration routes is determined by a comprehensive assessment of the nanostructure’s formulation characteristics, including solubility, stability, viscosity, and release kinetics, as well as by consideration of the intended therapeutic application and patient-specific requirements (Nasiri et al., 2024). The administration route is selected to optimize the bioavailability, efficacy, and safety profile of the nanostructure-based therapeutic. In certain embodiments, the DNA-origami nanostructures conjugated with folic acid as described herein are configured to carry at least one therapeutic agent and may be administered in a manner that enables controlled, sustained, or immediate release of said agent following administration (Lucas et al., 2022; He et al., 2023). The compositions may be formulated to deliver the therapeutic agent systemically or locally, depending on the intended clinical outcome (Pal & Rakshit, 2021). The dosage and administration regimen may be determined based on multiple factors, including but not limited to the mode of administration, the severity of the condition to be treated, the age, weight, and clinical status of the subject, and the pharmacokinetic and pharmacodynamic characteristics of both the DNA-origami carrier and the associated therapeutic payload (Schmidt et al., 2020; Nasiri et al., 2024). In some embodiments, the compositions may be administered in a single bolus dose, in repeated dosing regimens, orthrough sustained infusion protocols (Lucas et al., 2022). In various embodiments, the DNA-origami nanostructures function as a programmable carrier capable of encapsulating, adsorbing, or chemically binding one or more therapeutic agents (Ma et al., 2022). The release profile of the therapeutic agent may be tailored through modification of structural features of the nanostructure, including but not limited to base-pair sequence design, folding topology, crosslinking density, and surface charge (Ijas et al., 2019). Additionally, in certain embodiments, release may be governed by external or physiological triggers, such as enzymatic degradation, redox potential, temperature, or pH variation (Ijas et al., 2019; He et al., 2023). In some embodiments, the nanostructures are designed to provide an initial release of a therapeutically effective amount of the agent shortly after administration, followed by a sustained release phasethat maintains the therapeutic concentration within the desired range over an extended period (Lucas et al., 2022; He et al., 2023). This biphasic release may enhance efficacy while minimizing the frequency of administration and reducing systemic toxicity (Schmidt et al., 2020). The compositions may include pharmaceutically acceptable excipients, carriers, or stabilizers that support the preservation of structural integrity and biological activity of the nanostructure and the therapeutic agent during storage and upon delivery (Nasiri et al., 2024). The dosage of the therapeutic agent incorporated within the DNA-origami nanostructure is selected to provide a therapeutically effective amount upon release, taking into consideration the release kinetics and bioavailability of the formulation (Schmidt et al., 2020; He et al., 2023). In certain embodiments, the delivery system may be configured to preferentially accumulate in inflamed vascular tissues or immune sites relevant to the pathology of Takayasu arteritis, thereby enhancing the local concentration of the therapeutic agent and reducing off-target exposure (Thomas et al., 2011; Martin-Sabroso et al., 2022; Ma et al., 2022).

[0050] Technical Problem:

[0051] The currently available medications for Takayasu arteritis (TAK) remain inadequate in preventing cardiac tissue fibrosis or reversing arterial wall damage. Glucocorticoids (GC), the mainstay of treatment, are associated with significant adverse effects and lifethreatening complications, and have failed as monotherapy in approximately 70% of patients. Conventional synthetic DMARDs (csDMARDs) are commonly used in combination with GC, yet they are linked to high relapse rates and offer limited impact on vascular repair, and cyclophosphamide further presents long-term safety concerns, including the risk of infertility. Furthermore, several biological therapies have demonstrated limited effectiveness; anti-CD20 therapies have failed to control vascular inflammation, and anti-IL-6 receptor agents show relatively low efficacy, with their benefits diminishing without ongoing infusions. Although TNF-a inhibitors exhibit greater therapeutic effects, they often require high doses and frequent dose escalation, posing safety risks and leading to treatment resistance in some patients.

[0052] Accordingly, there is a need for a first-in-class therapeutic approach comprising a composition with selective targeting of M1 macrophages, which are key effector cells in the pathogenesis of TAK due to their secretion of pro-inflammatory cytokines, including IL-1 p, IL-6, and TNF-a. In certain embodiments, the composition further includes, but is not limited to, one or more anti-inflammatory compounds, immunomodulatory nucleic acids, and biologically active peptides capable of promoting cardiac tissue regeneration to address fibrosis in the arterial walls. Such a composition may also provide an upstream immunotherapeutic approach by targeting M1 macrophages, the source of key pro-inflammatory cytokines, rather than blocking individual cytokines like existing biologies. This strategy may offer broader, longer-lasting immune modulation with improved disease control and reduced reliance on GC treatments.Solution to the Problem:

[0053] The present invention provides a technical solution in the form of a pharmaceutical or biomedical composition comprising a three-dimensional triangular DNA origami nanostructure designed for targeted immunomodulation and tissue regeneration. The nanostructure is functionalized on its external surface with folic acid moieties to facilitate selective targeting of folate receptors, which are overexpressed on pro-inflammatory M1 macrophages. Upon interaction with M1 macrophages, the nanostructure induces their phenotypic polarization into the anti-inflammatory M2 phenotype. Additionally, the nanostructure can be engineered to encapsulate or conjugate one or more therapeutic agents, including but not limited to anti-inflammatory compounds, immunomodulatory nucleic acids, and biologically active peptides, enabling a dual mechanism of cellular modulation and therapeutic delivery. In some embodiments, the composition is further configured to promote cardiac tissue regeneration, particularly by addressing fibrosis in the arterial wall.

[0054] Advantageous Effects of Invention:

[0055] The invention provides a targeted approach for modulating immune responses and promoting tissue repair in Takayasu Arteritis (TAK). By selectively targeting folate receptors expressed on M1 macrophages, the composition exhibits high selectivity, thereby minimizing off-target effects and systemic toxicity. The polarization of macrophages into the M2 phenotype contributes to inflammation reduction, disease remission, and the elimination of reactive oxygen species (ROS) and nitric oxide (NO). The system further enables reversal of fibrotic changes in vascular tissues, contributing to enhanced vascular healing and cardiac tissue regeneration.

[0056] The invention offers a mechanistically upstream immunotherapeutic strategy by directly modulating M1 macrophages, the cellular source of key pro-inflammatory cytokines including IL-1 p, IL-6, and TNF-a. In contrast to existing biologic therapies that selectively inhibit individual cytokines, such as TNF-a or IL-6 inhibitors, the present invention addresses the root cellular drivers of inflammation. By targeting the origin ratherthan the downstream mediators of inflammatory signaling, the composition may exert broader and more sustained immunomodulatory effects. This mechanism positions the invention as a first-in-class therapy for Takayasu Arteritis (TAK), with the capability to improve overall disease control, reduce dependence on systemic glucocorticoids, and extend remission durations beyond those achieved by current biologic agents.

[0057] Evidence from related applications has shown that DNA nanostructures have an antiinflammatory effect in their nature, as they can scavenge reactive oxygen species (ROS) in other inflammatory and autoimmune diseases (Zhu et al., 2024).

[0058] Prior studies on DNA origami-based therapeutics have shown that the programmability and biocompatibility of DNA nanostructures offer distinct advantages for drug delivery.These structures can be precisely folded with addressable sites for loading small molecules, targeting ligands, peptides, and nucleic acids. They also enable tunable drug loading and release, enhance in vivo efficacy, and help overcome drug resistance. Compared to conventional methods, DNA nanostructure-based delivery systems provide improved targeting of disease-specific cell surface antigens, extended pharmacokinetic half-life, greater tissue and cell-specific delivery, and reduced side effects (Lucas et al., 2022).

[0059] Evidence from related applications showed that DNA origami nanostructures functionalized with anti-inflammatory drugs like IL-10 can significantly reduce inflammation and oxidative stress in vivo. In a diabetic mouse model of multi-organ failure, such nanostructures aggregated in inflamed tissues, lowering ROS levels while considerably improving organ function and survival. These findings lend support to the use of DNA origami-based platforms for anti-inflammatory and antioxidant treatments (Li et al., 2024).

[0060] A prior study found that the in vivo investigations on DNA nanostructures showed that they are not harmful to human or mouse cells, even at high concentrations, with only negligible toxicity, modest, transient immune activation that quickly declines, no weight loss or organ damage, and no cytokine storm even at high dosages (Lucas et al., 2022).

Claims

Claims:

1. A pharmaceutical or biomedical composition comprising a three-dimensional triangular DNA origami nanostructure functionalized with folic acid moieties on its external surface, wherein the nanostructure is configured to selectively target folate receptor beta (FRβ) expressed on pro-inflammatory M1 macrophages, and further wherein the nanostructure is engineered to encapsulate or conjugate one or more therapeutic agents selected from the group consisting of antiinflammatory compounds, immunomodulatory nucleic acids, and biologically active peptides.

2. The composition of claim 1, wherein the DNA origami nanostructure is assembled by folding a single-stranded DNA scaffold derived from the M13mp18 bacteriophage genome using a plurality of complementary staple strands, wherein the staple strands are designed to form a triangular prism-shaped conformation with lateral edge lengths ranging from approximately 50 nm to 100 nm.

3. The composition of claim 1 or 2, wherein the folic acid moieties are covalently attached to the staple strands of the DNA origami nanostructure via chemical linkages selected from the group consisting of EDC / NHS coupling, maleimide- thiol reaction, and strain-promoted azide-alkyne cycloaddition (SPAAC).

4. The composition of any one of claims 1-3, wherein the therapeutic agent is encapsulated within an interior cavity of the DNA origami nanostructure or conjugated to its surface via cleavable linkers responsive to intracellular stimuli, wherein the stimuli are selected from the group consisting of acidic pH, enzymatic activity, and redox potential.

5. The composition of any one of claims 1-4, wherein the therapeutic agent comprises an immunomodulatory nucleic acid selected from the group consisting of siRNA, miRNA, and antisense oligonucleotides.

6. The composition of any one of claims 1-4, wherein the therapeutic agent comprises a biologically active peptide selected from the group consisting of Hepatocyte Growth Factor (HGF), tissue-repairing peptides, and pro-regenerative peptides.

7. The composition of any one of claims 1 -6, wherein the DNA origami nanostructure is configured to induce phenotypic polarization of M1 macrophages into anti-inflammatory M2 macrophages upon cellular uptake.

8. The composition of any one of claims 1 -7, wherein the DNA origami nanostructure is further functionalized with targeting ligands or aptamers specific to additional biomarkers associated with Takayasu arteritis.

9. Amethod of treatingTakayasu arteritis (TAK) comprising administeringto a subject in need thereof a therapeutically effective amount of the composition of any one of claims 1-8, wherein the composition is administered via a routeselected from the group consisting of intravenous, intramuscular, and subcutaneous injection.

10. The method of claim 9, wherein the composition is administered in a single bolus dose, repeated dosing regimen, or sustained infusion protocol.

11. The method of claim 9 or 10, wherein the composition reduces vascular inflammation, promotes tissue repair, or extends remission duration in the subject.

12. A method of manufacturing the DNA origami nanostructure of any one of claims 1-8, comprising:a) designing a triangular prism-shaped DNA origami nanostructure using a single-stranded DNA scaffold and complementary staple strands; b) functionalizing the staple strands with folic acid moieties; andc) encapsulating or conjugating one or more therapeutic agents within or onto the nanostructure.

13. Use of the composition of any one of claims 1 -8 in the manufacture of a medicament for the treatment of Takayasu arteritis (TAK).

14. The use of claim 13, wherein the medicament is configured to target M1 macrophages, reduce pro-inflammatory cytokine secretion, or promote vascular tissue regeneration.